BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Registros relacionados

• Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
  por: Nyman, H, et al.
  Publicado em: (2009)
• Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
  por: Nyman, H, et al.
  Publicado em: (2009)
• The significance of FOXP1 in diffuse large B-cell lymphoma
  por: Gascoyne, D, et al.
  Publicado em: (2016)
• An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
  por: Marta Rodríguez, et al.
  Publicado em: (2022-08-01)
• MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
  por: Borovecki, A, et al.
  Publicado em: (2007)